A Phase 2 interventional study of NOE-115 in Menopause Syndrome, Menopause and Hot Flashes, sponsored by Noema Pharma AG. Completed at 5 sites in United States. Open to female participants aged 45 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-09-12.
Sponsored by Noema Pharma AG · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 193 studies in Hot Flashes with a site in United States — 26 open to participants now, 27 under way, 2 of them phase 3. Hot Flashes · United States.
Among the 193 studies in Hot Flashes with a site in United States, this one is the 122nd largest by enrollment of the 180 interventional ones that give a count, is one of 4 that started in 2024, is one of 41 in phase 2, and was the 169th registered.
339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.
Browse Hot Flashes studies →26 of the 193 studies in Hot Flashes with a site in United States are open now. Recruiting first, the newest first:
Spectrum Clinical Research, LLC · Sites in United States
Ages 45–65 · Women only
Dana-Farber Cancer Institute · Sites in United States
Ages 18+ · Men only
India Glycols Ltd · Sites in United States
Ages 45–60 · Women only
University of Kentucky · Sites in United States
Ages 18–99
University of Virginia · Sites in United States
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 37 Hot Flashes studies recruiting now, 13 (35%) set no upper age limit and 22 (59%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 45 Years to 60 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
193 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 48 · Phase 3 40 · Phase 4 14
First in 1997; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 90 across 306 interventional studies indexed under Hot Flashes.
Median enrollment 84 across the 180 interventional studies, 74 across the 6 observational. Of the 156 that completed or were terminated, 67 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 193 have an industry lead sponsor. The 10 most frequent:
Noema Pharma AG is the lead sponsor of 6 studies on the registry; none are open to participants now.
Noema Pharma AG has 1 study filed under Hot Flashes — fewer than ten, so there is no comparison to draw.
15 of the studies in Hot Flashes with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07903480Primal Harvest, LLCA Clinical Trial to Evaluate the Effects of A Supplement on Symptoms of Menopause and Overall Well-being | 2026-12 |
| NCT07751029Spectrum Clinical Research, LLCHaelan 951 for Menopause Symptoms in Peri- and Postmenopausal Women | 2026-12 |
| NCT05193968Mayo ClinicHot Flashes and Neurovascular Function in Women | 2026-12 |
| NCT07861295Vidya USA CorporationSatavari and Ashoka for Menopause (SAM) Study | 2026-12-01 |
| NCT07335224Inova Health Care ServicesMen With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 193 studies in Hot Flashes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety, tolerability, and preliminary effectiveness of NOE-115 on moderate to severe vasomotor symptoms (hot flashes) due to menopause in women.
This is a multi-center study to evaluate the effect of NOE-115, a monoamine modulator, in patients with moderate to severe vasomotor symptoms (hot flashes) due to menopause.
Women will participate in the study for a total of approximately 12 weeks, comprising a screening period (4 weeks), treatment period (4 weeks), and a follow up period (4 weeks).
The study is single arm but enrollment will occur in two cohorts. In Cohort, enrolled women will receive NOE-115 at a daily Dose A for the entire 4-week treatment period. Cohort 1 participants will return to the clinic on specified days per protocol for tolerability assessments.
Cohort 2 will enroll participants after the acceptable safety/tolerability of NOE-115 Dose A has been determined from Cohort 1.
Administration of NOE-115 will start on Study Day 1 and will continue daily for 4 weeks and will start at Dose A of NOE-115 as defined by the study protocol. Participants will receive NOE-115 up to a maximum- daily dose based on Investigator decision. Cohort 2 participants will return to the clinic on specified days per protocol for tolerability assessments and possible dose increases of NOE-115.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History of cardiovascular disease including:
a) Uncontrolled hypertension (systolic Blood Pressure (BP) > 165 mmHg or diastolic Blood Pressure > 100 mmHg) b) History of myocardial infarction, cardiac arrhythmia (other than sinus arrhythmia) c) Patients with a 12-lead Electrocardiogram (ECG demonstrating either of the following: corrected for heart rate according to Fridericia's formula (QTcF) ≥ 470 msec (average of 3 Electrocardiograms (ECGs) obtained at the Screening Visit and assessed by central reader) QRS interval > 120 msec at the Screening Visit (local reading) Arrhythmia (other than sinus arrhythmia), conduction abnormalities (Atrioventricular block Grade 1 is allowed)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Escalating doses of NOE-115 capsules
Drug: NOE-115
NOE-115 is an investigational monoamine modulator which has potential anti-inflammatory activity.
Withdrawals Due to Adverse Events While on NOE-115 for Any Reason
Occurrence of withdrawal from the study by the participant due to adverse event. An AE is defined as any unfavorable and untoward sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment that occurs during the course of the study
Time frame: 4 weeks
Number of Participants Who Experience at Least One or More Adverse Event and the Severity of the Adverse Events (AEs)
An AE is defined as any unfavorable and untoward sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment that occurs during the course of the study
Time frame: 4 weeks
Weekly Mean Change in the Severity of Hot Flashes from Baseline to Week 4
Severity of the hot flashes will be assessed by participants using a daily hot flash diary from baseline to Week 4 of the study
Time frame: 4 weeks
Weekly Mean Change in the Frequency (any severity) of Hot Flashes from Baseline to Week 4
Hot flash frequency will be assessed by participants using a daily hot flash diary from baseline to Week 4
Time frame: 4 weeks
Effect of NOE-115 as Assessed by Clinical Global Impression of Severity (CGI-S) from Baseline to Week 4
The CGI-S rating is based upon observed and reported symptoms, behavior, and function in the past seven days and asks the clinician one question: "Considering your total clinical experience with this particular population, how ill is the patient at this time?" which is rated on the following seven-point scale: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill patients
Time frame: 4 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2024 to primary completion in Aug 2025, 15 months.
Of 24 phase 2 interventional studies under Hot Flashes, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's 15 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Noema Pharma AG